Swine respiratory disease affects the respiratory tract of swine. It is one of the prevalent cause of death in nursery pigs and grower/finisher pigs. There are multiple pathogens, viruses, and other secondary causative agents that causes respiratory disease in swine. Primary pathogens that causes swine respiratory disease are Actinobacillus pleuropneumoniae (APP), Mycoplasma hyopneumoniae, Bordetella bronchiseptica, and Pasteurella multocida.
Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1274
Viral agents involved are porcine reproductive and respiratory syndrome (PRRS) virus and swine influenza virus (SIV). Various diseases that come under ambit of swine respiratory disease are mycoplasma pneumonia, swine influenza, classical swine fever atrophic rhinitis, pleuropneumonia, porcine reproductive and respiratory syndrome, and porcine circovirus type 2. These infectious agents together increase the severity of the disease.
According to the factsheet by United Nations Food and Agriculture Organization (UN-FAO) worldwide there is close to one billion headcount of swine. China has highest number of headcount, followed by the U.S. and EU. These regions are expected to drive growth of the respiratory disease treatment market, owing to high pork production.
Key players operating in the swine respiratory disease treatment market include Zoetis, Inc. Merck Animal Health, Bayer AG, Boehringer Ingelheim Vetmedica, Inc., Elanco Animal Health, Virbac Group, Norbrook, Ceva Santé Animale, Vetoquinol, Bimeda holdings PLC, and Agrilabs, Inc. In January 2018, FDA approved dose of 100 gram per ton feed for Lincomix (Product from Zoetis, Inc.), which contains lincomycin hydrochloride to reduce the severity of swine respiratory disease from mycoplasma hyopneumoniae. Lincomix is the only feed medication approved against mycoplasma hyopneumoniae, which is leading cause for swine pneumonia.
In 2016, Gamithromycin (ZACTRAN) was approved for use in pigs by USDA. In June 2017, a team of researchers from University of Leicester isolated 20 bacteriophages that targets 72 potential drug resistant bacteria in pigs. This bacteriophages were found to be more specific for treatment of bacterial infections in pigs. MSD Animal Health (known as Merck Animal Health in the U.S. and Canada) in November 2017, signed an agreement to acquire Vilsan Pharmaceuticals which is a division of Vimar Group, based in Turkey. Vilsan Pharmaceuticals holds significant share in animal health products in Turkey.
Read Full Report with TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1274
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.